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Abstract
Background:  β-Amyloid precursor protein (APP) has be e n  r e p o r t e d  t o  p l a y  a  r o l e  i n  t h e
outgrowth of neurites from cultured neurons. Both cell-surface APP and its soluble, ectodomain
cleavage product (APPs-α) have been implicated in regulating the length and branching of neurites
in a variety of assays, but the mechanism by which APP performs this function is not understood.
Results: Here, we report that APP is required for proper neurite outgrowth in a cell autonomous
manner, both in vitro and in vivo. Neurons that lack APP undergo elongation of their longest neurite.
Deletion of APLP1 or APLP2, homologues of APP, likewise stimulates neurite lengthening.
Intriguingly, wild-type neurons exposed to APPs-α, the principal cleavage product of APP, also
undergo neurite elongation. However, APPs-α is unable to stimulate neurite elongation in the
absence of cellular APP expression. The outgrowth-enhancing effects of both APPs-α and the
deletion of APP are inhibited by blocking antibodies to Integrin β1 (Itgβ1). Moreover, full length
APP interacts biochemically with Itgβ1, and APPs-α can interfere with this binding.
Conclusion: Our findings indicate that APPs-α regulates the function of APP in neurite outgrowth
via the novel mechanism of competing with the binding of APP to Itgβ1.
Background
β-Amyloid precursor protein (APP) is a type 1 membrane
glycoprotein found at the cell surface and in endosomal,
endoplasmic reticulum, and Golgi membranes in many
cell types [1-3]. APP is expressed in the developing and
mature brain at the somal cell surface, along growing
axons and at the axonal growth cone. Cleavage by β- and
then γ-secretase generates Aβ peptide, the apparent patho-
genic agent in Alzheimer's disease (reviewed in [4]). How-
ever, during brain development, a much larger fraction of
APP is processed by α-secretases, which cleave within the
Aβ sequence [5]. This cleavage releases a soluble, amino-
terminal APP fragment (referred to as APPs-α) and leaves
a membrane-retained carboxy-terminal fragment (CTF) of
83 amino acids (C83). γ-Secretase can then cleave C83,
yielding a free intracellular domain (AICD) and a small
secreted peptide termed p3 [6].
APP has two homologues in mouse, human and other
mammals, APLP1 and APLP2 [7,8], which also may be
processed by α-, β, and γ-secretases in a manner similar to
APP [9-13]. Targeted deletions of these genes reveal func-
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tional redundancy among the three APP family members.
Single genetic deletions in APP, APLP1 or APLP2 are each
viable, whereas APLP2 deletion in combination with
either APP or APLP1 deletion leads to early postnatal
lethality [14-16]. The in vivo effects of disruption of these
genes in mice have been difficult to pinpoint due to this
functional redundancy. However, cells from these mice
can be cultured and manipulated in vitro to examine the
phenotypic effects of these deletions in detail.
Neuronal and glial co-cultures plated from the hippoc-
ampi of APP knock-out mice displayed shorter axonal
outgrowth after 1 day in vitro (DIV) and longer axons after
3 DIV compared to neurons plated from wild-type brains
[17]. These results suggested that deletion of endogenous
APP initially inhibits neurite outgrowth but over time
stimulates neurite outgrowth, supporting the hypothesis
that APP may first regulate adhesion to the substratum
and then act to inhibit neurite outgrowth.
The secreted extracellular domain of APP, which is endog-
enously produced by α-secretase (APPs-α) or β-secretase
(APPs-β), has also been shown to play functional roles in
several assays. Although APPs-α can rescue some of the
effects of APP deletion [18], studies of neurite outgrowth
in culture have not directly tested whether APPs-α appli-
cation can rescue the effects of APP deletion. Although
neuronal and glial co-cultures from APP knock-out mouse
hippocampi displayed longer axons after 3 DIV than neu-
rons from wild-type brains [17], these authors found that
co-culture of wild-type or APP knock-out neurons with
APP knock-out astrocytes increased neurite outgrowth
[17]. The latter result taken by itself suggests that APPs
secreted by astrocytes would normally inhibit neurite out-
growth. In contrast, other studies have shown that exoge-
nous addition of APPs-α to cultured neurons actually
promotes neurite outgrowth in a fashion similar to delet-
ing APP in neural cultures. For example, APPs-α was
found to increase neurite outgrowth in several assays,
including in primary cortical cells [19], cortical explants
[20], and PC12 cells [21,22]. Interpretation of these vari-
ous results requires a more complex explanation for how
full length APP and soluble APPs-α from neurons and glia
interact functionally.
Several lines of evidence suggest that APP may interact
functionally with integrins to mediate neurite outgrowth.
Similar to APP, integrins have been shown to regulate
neurite outgrowth [23,24], and APP and integrins (α5, α1,
and β1) co-localize in developing neurons in both growth
cones and along axons [25-27]. However, no studies have
addressed whether APP and integrin family members
functionally or biochemically interact.
As reviewed above, both the absence of APP and the appli-
cation of its major secreted derivative (APPs-α) can elon-
gate neurites in culture. These seemingly paradoxical
observations, which we confirm herein, led us to hypoth-
esize that APPs-α may act to oppose effects of cell-surface
APP and its homologues by competitively binding to fac-
tors that normally interact with the holoprotein to inhibit
neurite outgrowth. Here, we show that deletion of each of
the full-length APP family members acts in a cell-autono-
mous manner to promote neurite outgrowth in primary
neuronal cells, and that adding the soluble derivative
from each APP family member to wild-type cells similarly
stimulates neurite outgrowth. Importantly, we show that
APPs-α does not stimulate neurite outgrowth in the
absence of APP. Our results support the hypothesis that
secreted APPs-α can inhibit the activity of cell-surface
APP. Further, we provide evidence that APP and APPs-α
can each interact biochemically and functionally with
integrins to mediate these effects.
Results
In order to confirm and extend previous studies showing
that APP plays a role in neurite outgrowth, we plated
embryonic day 18 (E18) primary hippocampal or cortical
neurons from APP knock out and wild-type littermate
mice on CC2 coated two-chamber slides. After 3 DIV, cells
were fixed and immunostained for βIII-tubulin, and the
length of the longest neurite (defined here as the axon)
was measured. Using these culture conditions, APP knock
out cultures displayed longer axons than did neurons in
wild-type cultures for both hippocampal (Figure 1a) and
cortical (Figure 1f) neurons.
Next, we sought to determine the effects of APPs-α in this
neurite outgrowth assay. Conditioned media (CM) from
either Chinese hamster ovary (CHO) cells stably express-
ing human APPs-α or untransfected (control) CHO cells
were added to wild-type E18 primary neurons for three
days. APPs-α in the CM was present over the 3-day period
after some degradation during the first 24 h (Figure 1c). In
agreement with previous studies, the CM of the APP-over-
expressing cells increased axon outgrowth over three days
(Figure 1b). We found that the CM of CHO lines stably
expressing APLP1 or APLP2 [10] conferred similar axon-
elongating activity (Figure 1b).
Besides APPs-α, whole CM from the CHO transfectants
contains numerous additional proteins that could act in
conjunction with or oppose the neurite-elongating activ-
ity of APPs-α. To assess whether APPs-α by itself can
induce axonal outgrowth, His-tagged APPs-α was purified
from baculovirus-transduced insect cells. Pure, recom-
binant APPs-α induced axonal outgrowth to a level simi-
lar to APPs-α from CM when similar concentrations of
APPs-α were applied (Figures 1c–e). In contrast, purifiedNeural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
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Loss of APP and APPs-α application each increase neurite length Figure 1
Loss of APP and APPs-α application each increase neurite length. E18 primary hippocampal or cortical neurons from 
wild-type (WT) or APP knock-out (APP KO) mice were treated as described. Three days later, the cells were fixed and immu-
nostained for βIII-tubulin, and neurite length was measured. (a) Comparison of neurite lengths of wild type and APP knock-out 
hippocampal neurons. (b) Comparison of neurite lengths of wild-type hippocampal neurons treated with CM from untrans-
fected, APPs, APLP1, or APLP2 expressing CHO cells. (c) Western blots for APPs (8E5) on CM from day 0 (d0), d1, or d2 
after addition to primary neurons (left panel) or western blot of equal amounts of purified APPs-α compared to APPs-α condi-
tioned media (right panel). (d) Silver stain of sequential purification steps of APPs-α from baculovirus-transduced insect cells. 
Left panel: lanes 1 and 2 are ammonium sulfate (A.S.) precipitations from 0–60% or 60–100%; lane 3 is the flow through (FT) 
after addition to a nickel chelating column; lanes 4–6 are washes from the column; and lanes 7–9 are elutes from column. Right 
panel: final purified product of APPs-α with mutation of cysteine 117 (see Materials and methods for details of purification). 
Bottom: western blot (WB) with an antibody that recognizes the extracellular domain of APP (8E5, Elan) (e) Quantification of 
neurite length after addition of purified APPs-α (wild type) at increasing concentrations or APPs-α (C117A) at 120 ng/ml. (f) 
E18 primary cortical neurons from APP knock-out or wild-type littermates were treated with CM from either CHO cells sta-
bly expressing APPs-α or control CHO cells. Three days later, cells were fixed and immunostained for βIII-tubulin, and neurite 
length was measured. Error bars represent standard error of the mean; *p < 0.05; ***p < 0.001.Neural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
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APPs-α with a mutation of cysteine 117, which is required
to form a disulfide bridge important for determining the
secondary structure of the extracellular domain of APP
[28], did not increase the length of neurites in this assay
(Figure 1d, e).
Because both loss of APP and addition of APPs-α induced
an increase in axonal outgrowth in this assay, we hypoth-
esized that APPs-α may bind to factors that the extracellu-
lar domain of cell-surface APP also binds to, thereby
acting to compete with cell-surface APP and inhibit its
neurite-regulating activity. As an initial test of this hypoth-
esis, we applied APPs-α to APP knock-out neurons to
investigate whether APPs-α would still increase axonal
outgrowth in the absence of cell surface APP. Although
APPs-α again increased axonal outgrowth in wild-type
neurons, it did not further increase outgrowth in neurons
plated from APP knock-out littermates (Figure 1f). This
result indicates that APP must be present for the neurite-
enhancing effects of APPs-α to occur.
When APP knock-out neurons are plated and examined
for effects on neurite outgrowth as above, the cultures lack
both full-length APP and secreted APPs-α. To determine
whether APP is required in a cell-autonomous manner for
neurite regulation, we transfected APP small hairpin RNAs
(shRNAs) into primary rat neurons at a low efficiency. We
purposefully achieved less than 1% transfection efficiency
in primary neurons using a modified lipofectamine proto-
col, in order to examine cell autonomous effects. Several
APP shRNAs were designed to target rodent APP, and two
shRNAs were selected that either efficiently knocked
down APP (APP-active) or did not knock it down (APP-
inactive) [29]. E17 primary rat neurons were transfected
with active or inactive APP shRNA plus green fluorescent
protein (GFP) or else with GFP alone, and three days later,
the cells were fixed and immunostained for βIII-tubulin.
The transfected neurons were identified by their GFP flu-
orescence (Figure 2a, b), and their longest neurites were
measured as before. Transfection of APP shRNA-active sig-
nificantly increased the length of the longest neurite rela-
tive to transfection with either APP shRNA-inactive or GFP
alone (Figure 2c), consistent with a cell-autonomous
function of APP in regulating neurite length.
Next, we sought to determine whether the effects on neu-
rites of altering APP expression that we observed in cul-
tured neurons also occurred in vivo. To this end, control
DNA (GFP alone) or APP shRNA-active plus GFP were
electroporated in utero into E14 or E17 neuronal precursor
cells lining the lateral ventricle of rat embryos. Data from
our lab and others have shown that the rate of co-electro-
poration of two plasmids of equal molarity is between
90% and 95%, and that in vivo electroporation of APP
shRNA and GFP results in an efficient knock down of APP
in GFP-positive, electroporated cells [29-31]. The electro-
porated embryos were harvested at postnatal day 5, and
their brains were fixed and sectioned coronally. With elec-
troporation of GFP alone, neuronal precursors migrated
into the cortical plate and differentiated, displaying radi-
ally aligned neurites, as expected (Figure 2d, f). Previ-
ously, we reported that co-electroporation of APP shRNA-
active and GFP resulted in a strong decrease in APP expres-
sion and a corresponding defect in entry into the cortical
plate for the large majority of developing neurons electro-
porated at E13 and harvested at E19, with greater than
80% of cells failing to migrate correctly [29]. Here, we
electroporated APP shRNA constructs at E14 and har-
vested at a postnatal time point (postnatal day 5) when
migration and differentiation are complete. The APP-
silenced cells continued to show a defect in cortical plate
entry at this late time point (Figure 2h versus 2i), and the
cells that were able to migrate into the cortical plate exhib-
ited abnormal neurites, with radial and tangential proc-
esses showing excessive branching and often a beaded
appearance in subsets of cells (Figure 2e, g).
The phenotype described above following knock down of
APP in vivo occurred in only a subset of cells and was dif-
ficult to quantify accurately. Therefore, in order to quan-
tify the qualitative phenotype we observed in vivo, regions
of the cortex electroporated at E14 were dissected two
days after electroporation (to allow time for APP knock
down) and cultured and analyzed using the same neurite
outgrowth assay described above. Similar to the in vitro
Lipofectamine transfection experiments, plating of the in
utero  electroporated cells revealed APP knockdown in
only a small subset of all of the neurons (less than 10%),
and GFP fluorescence was used to identify these electro-
porated cells. In agreement with the Lipofectamine trans-
fection experiments, cells electroporated in vivo with APP
shRNA-active displayed longer axons than those electro-
porated with GFP alone (Figure 2j). In addition, these
cells showed fewer primary neurites (Figure 2k), but there
was no significant difference in axonal branching between
control GFP electroporations and APP shRNA-active plus
GFP co-electroporations (data not shown).
APP has two family members (APLP1 and APLP2) that
appear to play redundant roles with APP for at least some
of its functions and may compensate for a loss of APP in
knock-out mice [14-16]. As shown in Figure 1b, APLP1-s
and APLP2-s application each induced an increase in
axonal outgrowth. In order to determine whether knock
down of APLP1 or APLP2 resulted in a similar increase in
axonal outgrowth, shRNAs were generated that efficiently
knock down each of these family members (Figure 2l, m)
and electroporated in utero and analyzed as described for
APP. These analyses showed a small but significant
increase in axonal outgrowth upon APLP1 knock downNeural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
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APP knock-down increases neurite length in a cell-autonomous manner Figure 2
APP knock-down increases neurite length in a cell-autonomous manner. (a, b) E17 primary cortical neurons were 
plated and transfected with plasmids encoding GFP alone (a) or GFP with APP shRNA-active (b) or with APP shRNA-inactive 
(not shown). Three days later, neurons were fixed and immunostained for βIII-tubulin. (c) Neurite length was quantified in 
GFP+, transfected cells. Error bars represent standard error of the mean; *p < 0.05; ***p < 0.001. (d-i) E17 (d, e) or E14 (f-i) 
cortices were electroporated with GFP (d, f, h) or GFP + APP shRNA-active (e, g, i) and harvested at postnatal day 5. Images 
in (d-g) are of the upper half of the cortical plate in coronal sections. (h, i) Coronal sections immunostained for Tbr1 (red), 
marking layer VI of the cortical plate (CP), and MAP2 (blue), marking the entire cortical plate. GFP positive, electroporated 
regions of E14 cortices were dissected 48 h after electroporation, dissociated, and plated. Three days later cells were fixed and 
immunostained for βIII-tubulin. IZ; intermediate zone; white lines delineates noted regions of the cortex (j, k) Neurite lengths 
(j) or the number of primary neurites (k) were quantified for GFP+ cells. Error bars represent standard error of the mean; *p 
< 0.05; ***p < 0.001. (l, m) FLAG-tagged murine APLP1 (l) or APLP2 (m) constructs were co-transfected into CHO cells with 
an empty vector or with three different shRNA constructs targeting rodent APLPs. Transfections (tf) of duplicate wells are 
shown. Forty-eight hours post-transfection, cells were lysed, and the western blots for FLAG on protein normalized samples 
are shown.Neural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
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(an increase with APLP2 knock down failed to reach sig-
nificance) and significant decreases in the number of pri-
mary neurites with knock down of APLP1 or APLP2,
relative to control GFP electroporations (Figure 2j, k).
Using this in vivo electroporation paradigm, the analysis is
limited to the specific subset of cells that are electropo-
rated (those that undergo their terminal mitosis on or
near E14, the day of electroporation). Therefore, the lack
of a significant change in axonal length with APLP2 knock
down may be due to high endogenous expression levels of
APLP2 in the subset of cortical cells electroporated at E14.
To test whether APLP2 expression could be observed in
embryonic cortical cells, APLP2 expression was analyzed
in E18 primary cortical cultures. In these cultures, APP
and APLP2 were expressed in similar patterns in cell bod-
ies, neurites and growth cones in a subset of cells (Figure
3a–d). To test if APLP2 contributes to axonal outgrowth in
such cells, primary neurons were plated from E18 APLP2
knock-out cortices. This analysis showed that deletion of
APLP2 inall cortical cells resulted in a significant increase
in axonal outgrowth (Figure 3e).
Previous studies have shown that APP and integrins co-
localize in primary neurons, specifically at points of sub-
strate contact [25-27]. Similar to APP family members,
APLP2 is expressed in primary neuronal processes and loss of APLP2 increases neurite length Figure 3
APLP2 is expressed in primary neuronal processes and loss of APLP2 increases neurite length. Primary E18 wild-
type neurons were plated and fixed six days later. Neurons were immunostained for (a, c, d) APP and (b, c, d) APLP2. (d, e) 
E18 primary hippocampal neurons from wild-type (WT) or APLP2 knock out (KO) mice were plated. Three days later, cells 
were fixed and immunostained for βIII-tubulin and neurite length was measured and quantified. Error bars represent standard 
error of the mean; *p < 0.05.Neural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
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integrins have been shown to regulate neurite outgrowth
(for review, see [32]. In order to determine whether APP
and integrins physically interact, CHO cells were tran-
siently transfected with FLAG-tagged murine Integrin β1
(Itgβ1-FLAG) and the 695 amino acid splice variant of
APP. The lysates of these cells were subjected to immuno-
precipitation for Itgβ1 with M2 anti-FLAG antibody, and
the immunoprecipitates were probed for APP, revealing
the co-immunoprecipitation of APP and Itgβ1 (Figure 4a).
The carboxy-terminal domains of both APP and Itgβ1
contain NPXY motifs, which have been shown to bind to
common interacting partners such as Fe65 and Dab1 (for
review, see [33,34]. To determine if this domain is neces-
sary for APP-Itgβ1 co-immunoprecipitation, APP with two
point mutations in this motif (APP-NATA) and the
cleaved extracellular domain of APP (APPs-α) were tested
for their ability to co-immunoprecipitate with Itgβ1. Both
APP-NATA and APPs-α were able to interact with Itgβ1
APP and Itgβ1 biochemically interact Figure 4
APP and Itgβ1 biochemically interact. (a) CHO cells were transiently transfected with constructs as shown. Co-immu-
noprecipitations of the resultant lysates were then performed with anti-FLAG agarose. Western blots for the amino terminus 
of APP (anti-APP; 22C11; Chemicon) or Itgβ1 (Cell Signaling): upper panels are western blots of lysates and lower panels show 
western blots of FLAG-immunoprecipitations (IP). The band denoted by the single asterisk is believed to be a background 
band. The band denoted by the double asterisks is the heavy chain of IgG. (b) CHO cells were transiently transfected with APP 
and Itgβ1-FLAG or another carboxy-terminally tagged type I-transmembrane domain protein, angiotensin converting enzyme 
(ACE). Co-immunoprecipitations of the resultant lysates were then performed with anti-FLAG agarose and western blotted 
(WB) for APP or FLAG, as shown. (c) CHO cells were transiently transfected with Itgβ1-FLAG and APP, APLP1, or APLP2. 
Co-immunoprecipitations of the resultant lysates were then performed with anti-FLAG agarose and western blotted for 
APLP1, APLP2, or Itgβ1, as shown. (d) Lysates from CHO cells, E18 rat primary neurons, rat cortex, or transfected CHO cells 
were immunoprecipitated for Itgβ1 and western blotted for APP. (e) Lysates from total mouse brain were immunoprecipi-
tated with antibodies directed to APP or Tbr1 (used as a control) for 30 minutes or overnight (O/N) and western blotted for 
Itgβ1, APP, or transferrin receptor as a negative control.Neural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
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(Figure 4a). In contrast, APPs-α with a point mutation in
cysteine 117 did not co-immunoprecipitate with Itgβ1.
Further, another type I transmembrane domain receptor
(angiotensin converting enzyme) that was also FLAG-
tagged at its carboxyl terminus and expressed at a level
similar to APP did not co-immunoprecipitated with APP
(Figure 4b). Similar to APP, APLP1 and APLP2 also co-
immunoprecipitated with Itgβ1 (Figure 4c). These immu-
noprecipitation experiments were all performed with
overexpressed proteins. In order to confirm that APP
interacts with Itgβ1 under endogenous conditions in neu-
ronal cells, co-immunoprecipitation experiments were
performed on these proteins from mouse and rat brain
homogenates, as well as in rat primary neurons, and these
all confirmed the interaction (Figure 4d, e).
To address whether APP and integrins interact function-
ally, E18 primary cortical neurons from wild-type or APP
knock-out mice were plated and treated with an Itgβ1
blocking antibody (Ha2/5; BD Biosciences; San Jose, CA,
USA) or an isotype-matched control antibody. Previous
experiments have shown that blocking Itgβ1 function has
been shown both to inhibit neurite outgrowth or to have
no effect, based upon the assay utilized [24,35,36]. Our
assay conditions did not reveal significant effects on neu-
rite length of application of the Itgβ1 blocking antibody to
wild-type neurons relative to the addition of the control
antibody (Figure 5a, b). However, application of the Itgβ1
blocking antibody to APP knock-out neurons or else to
APPs-α rich CM-treated cultures fully inhibited the axon-
outgrowth promoting effect of each of these (Figure 5a,
b).
Because APPs-α is able to biochemically interact with
Itgβ1 in a fashion similar to full length APP (Figure 4a),
we hypothesized that APPs-α may be able to compete
with full-length APP for binding to Itgβ1. To address this
possibility, APP with a carboxy-terminal FLAG tag (APP-
FLAG) was co-transfected with Itgβ1 into CHO cells. After
48 h, CM from cells expressing APPs-α or from untrans-
fected control cells was added to the co-transfected cul-
tures for 8–12 h. Cultures were then lysed, and APP and
Itgβ1 were co-immunoprecipitated with anti-FLAG agar-
ose (Figure 5c). In a second approach, Itgβ1-FLAG was co-
transfected with APP, and after 48 h, purified His-tagged
APP was applied to the cultures for 8–12 h (Figure 5d).
Quantification of these experiments using Licor imaging
showed that in the presence of APPs-α, there was an
approximately 70% decrease in the amount of APP-Itgβ1
co-immunoprecipitated relative to the amount of immu-
noprecipitated FLAG-tagged construct using both of these
experimental approaches (Figure 5c, d). These results sug-
gest that APPs-α can compete with full-length APP for
binding to Itgβ1.
Discussion
Studies from multiple labs have now established that APP
plays a role in neurite outgrowth. However, the findings
are sometimes inconsistent as to whether APP enhances or
inhibits neurite outgrowth. It appears that APP may have
differential effects on outgrowth and branching of neur-
ites depending on the type of neuronal culture assayed
(dissociated primary neurons, explants, or immortalized
neuronal cell lines), the timing of analysis after plating (1
day versus 3 days versus 5 days), and the substrate upon
which the neurons are plated (CC2, laminin, poly-D-
lysine, fibronectin, and so on). In order to address the
mechanism through which APP is acting to affect neurite
outgrowth, we utilized a single primary neuronal culture
system to directly compare the effects of genetic loss of
APP and the application of APPs-α.
Loss of APP through either genomic deletion or shRNA-
induced silencing resulted in significantly increased neur-
ite elongation. Similarly, APPs-α application significantly
stimulated outgrowth of the longest neurite in the same
assay but, importantly, had no effect in cells that did not
express APP. These results support our hypothesis that
APPs-α acts to enhance neuronal process outgrowth by
inhibiting the activity of cell surface APP, as diagrammed
in Figure 5e. It should be noted that there are other possi-
ble explanations for the result; for example, the neuronal
processes may not be competent to grow any longer
beyond the length observed with APP deletion after 3 DIV.
However, further support for the hypothesis derives from
our experiments showing that APPs-α is able to block
both the physical and functional interaction of full length
APP and Itgβ1 (Figure 5). The model in Figure 5e incorpo-
rates these data to schematize the interactions we have
shown to regulate neurite outgrowth in our assay. Under
'wild-type' conditions, APP inhibits the outgrowth-pro-
moting activity of Itgβ1. In the absence of APP (that is, in
APP knock out neurons or APP shRNA-transfected neu-
rons), Itgβ1 enhances neurite outgrowth. Application of
APPs-α to wild-type neurons can compete with cell sur-
face APP for binding to Itgβ1 (as we demonstrate in Figure
5c, d), thus inhibiting the ability of APP to regulate Itgβ1-
induced neurite outgrowth. In the absence of cell surface
APP, APPs-α has no effect.
Like APP family members, integrins are single-pass, type 1
transmembrane proteins that mediate adhesion to extra-
cellular matrix factors and regulate neurite outgrowth
(reviewed in [37]). Integrins exist as heterodimers, and
previous studies have shown that APP co-localizes with
integrin α 1β1 and α 5β1 heterodimers in growth cones
[25,26,38] and at point contacts but not focal adhesions
in embryonic neurons [25]. Based upon data presented
here, the extracellular domain of APP is able to interact
with Itgβ1, and APPs-α can compete with full length APPNeural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
Page 9 of 13
(page number not for citation purposes)
Itgβ1 blocking antibody inhibits the effects on neurite outgrowth of APPs-α or deletion of APP Figure 5
Itgβ1 blocking antibody inhibits the effects on neurite outgrowth of APPs-α or deletion of APP. (a) E18 primary 
cortical neurons from wild-type (WT) or APP knock-out (KO) mice were treated with Itgβ1 blocking antibody or control (ctl) 
antibody. (b) Wild-type E18 neurons were treated with control or APPs-rich CHO CM together with either Itgβ1 blocking or 
control antibody. The longest βIII-tubulin-positive neurites were quantified. Error bars represent standard error of the mean; 
***p < 0.001; ns, not significant. (c, d) CHO cells were transfected with APP-FLAG and Itgβ1 (c) or Itgβ1-FLAG and APP (d). 
Example of western blot (WB) of co-immunoprecipitates of APP and Itgβ1 after incubation with control (ctl) CM or APPs-α 
CM (c) or purified His-tagged APPs-α (d) with quantification below; error bars represent standard deviation between duplicate 
wells. A significant decrease in co-immunoprecipitation between APP and Itgβ1 was observed between multiple experiments; p 
< 0.05. (e) Model for proposed functional interaction between APP and integrins in regulating neurite elongation.Neural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
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for binding to Itgβ1 at the cell surface. Both APP and Itgβ1
have NPXY motifs that interact with Fe65, a cytoplasmic
adaptor protein that has the ability to bind two NPXY
motifs simultaneously to form tripartite complexes, as it
does with APP and LRP [39,40]. However, full length APP
with mutations of its NPXY domain retains the ability to
interact with Itgβ1. Thus, APP is likely to interact with
Itgβ1 through both its extracellular domain and indirectly
through its intracellular domain via interactions with
adaptor proteins such as Fe65. In agreement with a role
for Fe65 in this process, Fe65 has been found to co-local-
ize with APP and Itgβ1 in growth cones [26], and it was
recently shown that blocking the ability of Fe65 to bind to
APP slowed axonal outgrowth [41]. Our results showing a
biochemical interaction between APP and Itgβ1 are in
agreement with recent studies presented by the Rebeck lab
[42].
The two other members of the mammalian APP family,
APLP1 and APLP2, are also processed by α-, β-, and γ-
secretases, releasing analogous cleavage products. The car-
boxy-terminal domains of all three family members are
highly similar in amino acid sequence, but their extracel-
lular domains are quite divergent. Surprisingly, the solu-
ble cleavage products of APLP1 and APLP2 also
stimulated neurite outgrowth in our in vitro assay. In addi-
tion, we observed that knock down or knock out of APLP1
and APLP2 in neurons resulted in an increase in neurite
length, similar to the situation in APP knock-out neurons,
suggesting that APLP1 and APLP2 at the cell surface can
also regulate neurite outgrowth. Moreover, we found that
full length APLP1 and APLP2 also interact with Itgβ1.
Taken together, these results suggest that APP family
members all play a role in regulating neurite outgrowth.
Conclusion
We recently showed that acute APP knock-down in
embryonic rodent cortex dramatically retards the migra-
tion of cortical precursor cells into the cortical plate [29].
In addition, we show here that APP knock-down in the
cortex results in neurons that display abnormally formed
and disorganized neurites. Each of these effects was due to
a cell-autonomous loss of APP, as the total number of
cells receiving APP shRNA was very low, and full length
APP at the cell surface appears to mediate these effects. We
hypothesize that the effects of loss of APP on neuronal
precursor migration and neurite outgrowth are function-
ally linked through the ability of APP to differentially
interact with factors at or near the cell surface (for exam-
ple, Itgβ1), and that APPs-α may regulate each of these
processes.
A recent study showed that knock-in of APPs-α to the APP
genomic locus can rescue many of the defects observed in
APP knock out animals, including reductions in brain and
body weight, defects in long term potentiation, and cer-
tain behavioral defects in spatial learning, exploratory
activity, and locomotor activities [18]. These studies sug-
gest that APPs-α can substitute for a deletion of APP to
regulate these processes. However, we find that APPs-α
does not rescue defects in neurite outgrowth observed
upon deletion of APP. Rather, APPs-α application to wild-
type neurons phenocopies APP deletion. Similarly, migra-
tion defects observed upon APP loss-of-function also are
not rescued by APPs-α, and full length APP is required for
cortical plate entry [29]. Thus, both full length APP and its
principal cleavage product APPs-α can apparently act as
independent factors with multiple, sometimes distinct
activities. Whereas APPs-α has evolved its own independ-
ent functions [18], our results indicate that it also has the
ability to regulate the function of full length APP in some
developmental processes.
Materials and methods
Neurite outgrowth assays
Sprague Dawley rats and C57BL6 mice were obtained
from Charles River (Boston, MA, USA) and Taconic
(Albany, NY, USA). APP knock out and APLP2 knock out
mice were obtained form Jackson Labs (Bar Harbor, ME,
USA). Hippocampal and cortical primary neurons were
plated and cultured as described with the following
changes [17]. Briefly, E17 or E18 hippocampi or cortices
were dissected, and dissociated with trypsin-EDTA. Cells
were plated onto LabTek CC2 coated two-well chamber
slides (Thermofisher; Rochester, NY, USA) in 'plating
media' (Dulbecco's modified Eagle's medium + 5% fetal
calf serum + penicillin/streptomycin). Then, 2–4 h after
plating, media was changed to Neurobasal medium con-
taining B27 supplement. After 3 DIV, neurons were fixed
in 4% paraformaldehyde, washed with phosphate-buff-
ered saline (PBS), blocked in 2% donkey serum plus 0.1%
Triton X-100, and outgrowth was examined by immunos-
taining with anti-βIII-tubulin antibody (1:1,000; Milli-
pore, Billerica, MA, USA). Neurite outgrowth was
quantified by imaging neurons on a Zeiss Axioskop and
digital images were acquired with an MC100 camera sys-
tem. Neuronal processes were then analyzed using Axiovi-
sion LE 4.4 software. For each graph, data on neurite
length were generated from at least two independent sets
of neurons (for each condition) and greater than 200 cells
were counted for each condition for each experiment
(with the exception of neurons transfected with shRNA
constructs, where 50–150 cells were counted per experi-
ment). Significance was determined using Kruskal-Wallis
nonparametric ANOVA and Dunn multiple comparisons
tests. All analysis was performed blind.
For shRNA transfections, neurons were plated on CC2-
coated two-chambered slides (LabTek). Three hours after
plating, each well was transfected with 600 ng of shRNANeural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
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and 400 ng of GFP plasmid using 2 μl of Lipofectamine.
Three hours post-transfection, media was changed to Neu-
robasal with B27 supplement and analyzed as above.
For integrin antibody blocking experiments, primary neu-
rons were plated as above, and Armenian hamster anti-
CD29 (Itgβ1; 50 μl; BD Biosciences)or an isotype
matched control antibody (50 μl; BD Biosciences) was
added to culture media when media was changed to Neu-
robasal with B27 supplement. Neurite outgrowth was
then analyzed as above.
CM from CHO cell lines stably expressing APPs-α (M
Townsend and DJ Selkoe, unpublished or control CHO
was collected and concentrated using a YM-3 Centricon
filter (Thermofisher; Rochester, NY, USA). Similarly, CM
from cell lines stably transfected with human APLP1 and
APLP2 [10] was collected and concentrated. CM was
added to neuronal cultures on the day of plating and ana-
lyzed as above.
For purification of human APPs-α (wild type), the APP
ectodomain, spanning amino acids 1–612 (ending at the
α-secretase cleavage site, APPs-α) and containing a car-
boxy-terminal six-histidine tag was cloned into a transfer
vector for generation of recombinant baculovirus. APPs-α
protein was expressed using a baculovirus expression sys-
tem, which was performed at the Wistar Institute at the
University of Pennsylvania. Briefly, recombinant baculo-
virus containing the APPs-α gene was generated and used
to infect High Five cells (Trichoplusia ni). Cells were grown
for 48 h to allow for protein expression and secretion
before CM was harvested for purification. APPs-α was
purified to homogeneity first through an ammonium sul-
fate precipitation (0–60%) cut and followed by an immo-
bilized metal affinity chromatography (nickel chelating)
purification (for binding: 20 mM sodium phosphate; 500
mM NaCl; 20 mM imidazole; wash: 80 mM imidazole;
elute: 150 mM imidazole). Following purification, APPs-
α was dialyzed against PBS. Purification of human APPs-
α C117A was slightly modified due to the low expression
levels of mutant APPs: rather than purification from CM,
purification was from transfected High Five cell pellets
lysed in RIPA buffer.
In utero electroporation
Sprague Dawley rats (Charles River) were housed and
cared for under the guidelines established by University of
Connecticut and Harvard University's Institutional Ani-
mal Care and Use Committees (IACUC) in compliance
with federal standards. Timed pregnant rats (E13 or E17)
were anesthetized with Ketamine/Xylazine (100/10 mix-
ture, 0.1 mg per g body weight, intraperitoneally). The
uterine horns were exposed, and a lateral ventricle of each
embryo injected with DNA constructs and Fast Green (2
mg/ml; Sigma; St. Louis, MO) via a microinjector (Picosp-
ritzer III, General Valve; Fairfield, NJ, USA) and pulled
glass capillaries. shRNA constructs (1.0–1.5 μg/μl) was co-
electroporated with 0.5 μg/μl pCAG-GFP. Electroporation
was accomplished with a BTX square wave electroporator,
at 75 V, for 50 ms on followed my 950 ms off for 5 pulses.
The voltage was discharged across copper alloy oval plates
placed on the uterine wall across the head of the embryo.
Brains from postnatal pups were harvested in 4% parafor-
maldehyde by cardiac perfusion, sectioned coronally, and
immunostained for Tbr1 (1:1,000; Millipore) and MAP2
(1:5,000; Abcam, Cambrige, MA, USA). Images were
acquired using a Zeiss LSM 510 confocal microscope with
Axiovert 100 M system.
For neurite outgrowth quantitative analysis, E14 rat corti-
ces were electroporated as described above. Then, 48 h
after electroporation, whole brains were dissected in
Hanks Balanced Salt solution (Gibco Invitrogen;
Carlsbad, CA, USA), and GFP positive regions of the cor-
tex were dissected out. Regions of electroporation from at
least five independent brains for each condition were dis-
sected and pooled. These electroporated regions were then
dissociated and plated on CC2-coated two-chamber
slides. Three days after plating, cells were fixed, immunos-
tained, and analyzed as described above.
Immunostaining
Primary E18 wild-type neurons were plated and fixed six
days later. Neurons were fixed in 4% paraformaldehyde,
then incubated in blocking buffer (2% donkey serum;
0.005% Triton X-100 in PBS) for greater than 1 h. Sections
were then incubated in primary antibody (for APP:
22C11; 1:500; Millipore; for APLP2: W2CT; 1:500 [10])
overnight at 4°C, followed by three washes in PBS. Sec-
tions were then incubated with Cy3- and Cy2-conjugated
secondary antibodies (1:500; Jackson Immunoresearch;
West Grove, PA, USA) for greater than 1 h followed by
four PBS washes. Sections were mounted with glass cover
slips using GelMount (Biomeda Plovdiv, Bulgaria).
Images were acquired using a Zeiss LSM 510 confocal
microscope with Axiovert 100 M system.
Plasmid generation
APP shRNA generation and testing were described previ-
ously [29]. shRNA constructs were generated in the
pENTR-U6 vector (Invitrogen)with the following
sequences: APP shRNA-inactive, gctgacaagaaggccgttatc;
APP shRNA-active, gcactaacttgcacgactatg; APLP1 shRNA2
(active), cagattaatgaggtgatgc; APLP2 shRNA2 (active),
gccacatcgcattcttcaagc. shRNAs were tested by transient co-
transfections (Lipofectamine, Invitrogen) in CHO cells of
shRNA construct (or vector) and carboxy-terminally
FLAG-tagged APLP1 or APLP2. Cells were lysed after 48 h
in 1% NP-40 STEN buffer (150 mM sodium chloride, 50Neural Development 2008, 3:15 http://www.neuraldevelopment.com/content/3/1/15
Page 12 of 13
(page number not for citation purposes)
mM Tris, 2 mM EDTA and 1.0% (v/v) Nonidet P-40).
Lysates were electrophoresed on 10–20% Tricine gels
(Invitrogen) and transferred to nitrocellulose. Western
blotting was performed with anti-M2 FLAG (1:1,000;
Sigma) and IRDye800-conjugated anti-mouse secondary
antibody (1:10,000; Rockland Immunochemicals, Gil-
bertsville, PA, USA) and detected using the Licor detection
system.
Carboxy-terminally tagged murine APP with the FLAG
epitope and carboxy-terminally tagged mouse Itgβ1 with
the FLAG epitope were cloned into the pCAGGs plasmid,
which drives expression under the chicken β-actin pro-
moter and the CMV enhancer. FLAG-tagged angiotensin
converting enzyme cDNA was cloned previously as
described [43].
Immunoprecipitation and western blotting
CHO cells were transiently co-transfected using Lipo-
fectamine 2000 (Invitrogen) in 10 cm dishes with murine
Itgβ1 with a carboxy-terminal FLAG tag with either vector
alone or with human APP of the 695 or 751 splice vari-
ants, APP harboring two point mutations in the NPXY
domain of APP (APP-NATA), APPs-α, APLP1, or APLP2.
Cells were lysed after 48 h in 1% NP-40 STEN buffer (150
mM sodium chloride, 50 mM Tris, 2 mM EDTA and 1.0%
(v/v) Nonidet P-40). Lysates were immunoprecipitated
with M2-agarose (Sigma). Immunoprecipitations then
were electrophoresed on 10–20% Tricine gels (Invitro-
gen) and transferred to nitrocellulose. Western blotting
was performed with anti-APP (C9; 1:1,000; Selkoe lab),
anti-APP (22C11; 1:500; Millipore), anti- APLP1 (WINT;
1:500; gift of D Walsh), or APLP2 (W2CT; 1:500; gift of D
Walsh) and IRDye800- or IRDye680-conjugated second-
ary antibodies (1:10,000; Rockland Immunochemicals)
and detected using the Licor detection system.
Similarly, APP-FLAG and human Itgβ1 were co-trans-
fected into CHO cells. After 48 h, CM from control CHO
cells or APPs-α CHO cells was applied to transfected cells
for 8–12 h. Cells were lysed as above, immunoprecipi-
tated with M2-agarose, and western blots performed with
anti-APP as above and anti-Itgβ1 (Millipore). Alterna-
tively, APP and Itgβ1-FLAG were co-transfected as above
and purified APPs-α applied to transfected cells for 8–12
h, lysed and immunoblotted as above.
For endogenous co-immunoprecipitations, lysates from
E18 rat primary neurons, rat cortices, mouse brains, CHO
cells, or transfected CHO cells were immunoprecipitated
with anti-Itgβ1 (MAB 1997; Millipore), anti-APP (C9;
Selkoe Lab), or anti-Tbr1 as a control (Abcam).
Abbreviations
APP: β-Amyloid precursor protein; CHO: Chinese ham-
ster ovary; CM: conditioned media; DIV: days in vitro; E:
embryonic day; GFP: green fluorescent protein; Itgβ1:
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